Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCADE phase 3 trial of HC-1119 versus enzalutamide in metastatic castration-resistant prostate cancer
CTR20190794Phase 3Active
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deutenzalutamide, enzalutamide in prostate cancer (PCa), sponsored by Hinova Pharmaceuticals Inc.. Started Apr 2021; status: active.
02
Drugs
deutenzalutamideenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20190794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190794.